lenalidomide has been researched along with 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) | Trials (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) | Recent Studies (post-2010) (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 25 | 1 | 25 |
| Protein | Taxonomy | lenalidomide (IC50) | 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0972 | |
| Cyclin-K | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.007 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.009 | |
| Cyclin-A2 | Homo sapiens (human) | 0.013 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0282 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0397 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0257 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0027 | |
| Cyclin-H | Homo sapiens (human) | 0.02 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.02 | |
| Cyclin-A1 | Homo sapiens (human) | 0.013 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.0063 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.0037 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.073 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
1 other study(ies) available for lenalidomide and 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
| Article | Year |
|---|---|
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |